Real-world management of targeted therapies in chronic lymphocytic leukemia

Abstract

The advent of novel targeted therapies, including B-cell receptor (BCR) pathway and B-cell lymphoma 2 (BCL2) inhibitors, has substantially changed the treatment paradigm for chronic lymphocytic leukemia (CLL). Although targeted therapies have improved outcomes compared to traditional chemoimmunotherapy in the front-line and relapsed or refractory settings, they are associated with resistance mutations and suboptimal outcomes in certain high-risk patients. Additionally, targeted therapies are associated with drug interactions and unique adverse effect profiles which can be challenging for patients and clinicians to manage. Ongoing studies continue to address questions regarding optimal sequencing of therapies, the role of treatment combinations, and the efficacy of next-generation novel agents. This review provides a comprehensive overview regarding the clinical management of targeted therapies for CLL and applies current literature to clinical practice.

Tetrabromobisphenol A effects on differentiating mouse embryonic stem cells reveals unexpected impact on immune system

“…The fact that BTK is a key mediator of innate immunity and inflammation ( Weber et al, 2017 ; Weber, 2021 ) strongly suggest that TBBPA has the potential to lead to a strong imbalance, which in turn could induce and/or aggravate damages to the BBB integrity ( Ní Chasaide and Lynch, 2020 ), and permeate TBBPA in the central nervous system with more direct effects. Of note, BTK inhibitor share a variety of clinical applications, ranging from treatment of B cell malignancies, to autoimmune diseases and COVID-19 ( Zhu et al, 2021 ; Malekinejad et al, 2022 ; Rezaei et al, 2022 ; Weis et al, 2022 ), which raise the question on whether TBBPA may interfere with these therapeutic actions. This will certainly require dedicated experimental exploration and validation.…”

Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure

“…With the introduction of molecularly targeted agents for specific druggable proteins that are overexpressed in leukemia, an additional safety margin is added. Newer clinical treatments for B-cell leukemia targeted to molecular checkpoints can be divided into three groups of compounds that inhibit the uncontrolled growth of B cells: (1) Bcl-2, a mitochondrial antiapoptotic protein, (2) Bruton’s tyrosine kinase (BTK) inhibitors (TKI’s), (3) monoclonal antibodies, several of which are targeted to CD20, a surface antigen on B cells [ 5 ]. As molecularly targeted agents, these three compounds reduce off-target toxicities compared to earlier drugs, making them a preferred treatment option for patients from a wide demographic range [ 6 ].…”